Vericiguat

Vericiguat is a medication belonging to the class of soluble guanylate cyclase (sGC) stimulators. It works by enhancing the sensitivity of sGC to endogenous nitric oxide, leading to increased cyclic guanosine monophosphate (cGMP) levels. This mechanism of action results in vasodilation and improved cardiac function, making it useful in the management of certain cardiovascular conditions.

Indications

Vericiguat is indicated for the treatment of adults with symptomatic chronic heart failure and reduced ejection fraction (HFrEF) to reduce the risk of cardiovascular death and heart failure hospitalization when added to standard therapy.

Dosage

The recommended starting dose of vericiguat is 2.5 mg once daily, which may be increased to 5 mg once daily based on tolerability. Vericiguat should be taken with or without food.

Contra-Indications

Vericiguat is contraindicated in patients with a history of hypersensitivity to the drug or any of its components. It should not be used concomitantly with nitric oxide donors or phosphodiesterase inhibitors due to the risk of hypotension.

Special Precautions

Caution should be exercised when prescribing vericiguat to patients with hypotension, renal impairment, or hepatic impairment. Close monitoring of blood pressure, renal function, and liver function is recommended during treatment.

Side Effects

Common side effects of vericiguat include hypotension, headache, dizziness, and diarrhea. Serious adverse reactions may include renal impairment, hypotension, and fetal harm if used during pregnancy.

Drug Interactions

Vericiguat may interact with drugs that affect the nitric oxide-cGMP pathway, such as phosphodiesterase inhibitors and nitric oxide donors. Concomitant use of these medications should be avoided to prevent additive hypotensive effects.